Eleonora Dehlink

Dr. Eleonora Dehlink

Medical University of Vienna, Department of Pediatrics and Adolescent Medicine

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CBChristina Bannert
Christina Bannert
BBBettina Bidmon-Fliegenschnee
Bettina Bidmon-Fliegenschnee
GSGeorg Stary
Georg Stary
FHFlorian Hotzy
Florian Hotzy
JSJudith Stift
Judith Stift
EDEleonora Dehlink
Eleonora Dehlink
The role of the high affinity IgE receptor, FcεRI, in IgE-mediated immune responses of the gastrointestinal (GI) mucosa is poorly understood. Currently, a detailed characterization of FcεRI expression throughout the human gut is lacking. The aim of this study was to define the expression pattern of FcεRI in the GI tract. We compared FcεRI expression in children with gastritis/esophagitis (n = 10), celiac disease (n = 10), inflammatory bowel disease (IBD) (n = 9), and normal mucosa (n = 5). The α–subunit of FcεRI (FcεRIα), detected by immunohistochemistry, was found on cells infiltrating the mucosa of the esophagus, the stomach, and the duodenum, but was rarely detected in more distal sections of the GI tract. Accordingly, quantitative RT-PCR analysis on esophagus, stomach, duodenum, colon, and rectum biopsies revealed that FcεRIα and -β expression levels decreased towards the distal intestine. mRNA transcripts of the common Fc-receptor-γ chain were present in the entire GI mucosa. Double-immunofluorescence staining of esophageal specimens confirmed that FcεRIα was expressed on intraepithelial mast cells and Langerhans cells. The mRNA expression levels of the α, β, and γ subunits of FcεRI did not correlate with total serum IgE but were associated with mucosal inflammation. Our data define the upper GI tract as the main site for IgE-mediated immune activation via FcεRI. Tissue mRNA levels of FcεRIα are regulated by inflammatory conditions rather than serum IgE, indicating that FcεRI might also play a role in pathologies other than allergy.

21 December 2020 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
SRSabine Renner
Sabine Renner
ENEdith Nachbaur
Edith Nachbaur
PJPeter Jaksch
Peter Jaksch
EDEleonora Dehlink
Eleonora Dehlink
Cystic fibrosis is the most common autosomal-recessive metabolic disease in the Western world. Impaired trans-membrane chloride transport via the cystic fibrosis transmembrane conductance regulator (CFTR) protein causes thickened body fluids. In the respiratory system, this leads to chronic suppurative cough and recurrent pulmonary infective exacerbations, resulting in progressive lung damage and respiratory failure. Whilst the impact of bacterial infections on CF lung disease has long been recognized, our understanding of pulmonary mycosis is less clear. The range and detection rates of fungal taxa isolated from CF airway samples are expanding, however, in the absence of consensus criteria and univocal treatment protocols for most respiratory fungal conditions, interpretation of laboratory reports and the decision to treat remain challenging. In this review, we give an overview on fungal airway infections in CF and CF-lung transplant recipients and focus on the most common fungal taxa detected in CF, Aspergillus fumigatus, Candida spp., Scedosporium apiospermum complex, Lomentospora species, and Exophiala dermatitidis, their clinical presentations, common treatments and prophylactic strategies, and clinical challenges from a physician’s point of view.

4 June 2004 in Allergy
Verified
Journal Article
Closed access
PDF file
EDEleonora Dehlink
Eleonora Dehlink
CPC. Prandstetter
C. Prandstetter
TET. Eiwegger
T. Eiwegger
BPB. Putschogl
B. Putschogl
RUR. Urbanek
R. Urbanek
ZSZsolt Szepfalusi
Zsolt Szepfalusi

25 April 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JSJustyna Sieber
Justyna Sieber
NMNicole Martin
Nicole Martin
KSKlara Schmidthaler
Klara Schmidthaler
RGRené Gaupmann
René Gaupmann
EDEleonora Dehlink
Eleonora Dehlink
SGSaskia Gruber
Saskia Gruber
Background/Objectives: Patients with chronic lung diseases, such as cystic fibrosis, were considered a risk group for a severe course of coronavirus disease 2019 at the beginning of the pandemic. However, mounting evidence suggests that this group may not face an elevated risk for a severe SARS-CoV-2 infection. Methods: Here, we present data on the incidence and clinical course of SARS-CoV-2 infections in a single pediatric CF centre in Austria. Clinical variables were analyzed for their potential impact on disease acquisition and severity. A total of 135 young people with CF were assessed from February 2020 until December 2022. Results: Eighty-four patients were infected with SARS-CoV-2, out of which nine patients reported re-infection, resulting in 93 SARS-CoV-2 infections. Most infections, 76/93 (82%), occurred during the period of omicron variant predominance. Higher body mass index and respiratory colonization with Haemophilus influenzae before the beginning of the pandemic were significantly associated with the risk of acquiring SARS-CoV-2 infection. All patients had an uncomplicated COVID-19 course, regardless of the SARS-CoV-2 variant and COVID-19 vaccine status at infection. The most frequent symptoms were rhinitis (53%), fatigue (49%), cephalea (43%), and fever (38%). Neither oxygen therapy nor hospitalization were needed for any of the patients. Lung function parameters (FEV1, FVC, FEF50, LCI), both in the early post-viral as well as late post-viral stages, were not significantly impacted by SARS-CoV-2 infections. No long-term post-COVID-19 effects were reported. Conclusions: Our single-centre experience suggests that the course of SARS-CoV-2 infections in children and adolescents with CF is primarily mild and uncomplicated.


1 February 2007 in Allergo Journal
Verified
Journal Article
Closed access
KBK. Blaser
K. Blaser
ZSZ. Szépfalusi
Z. Szépfalusi
TET. Eiwegger
T. Eiwegger
EME. Mayer
E. Mayer
EDEleonora Dehlink
Eleonora Dehlink
KBK. Beyer
K. Beyer